SRTS News & Events

Reports Q1 revenue $3.4M, consensus $5.32M. "During the first quarter, we began our efforts in educating and training our existing customer base as well as our many new prospects. We are seeing the benefits of the dedicated CPT Codes for superficial radiotherapy move from concept to commercial reality," said Joseph Sardano, Chairman and Chief Executive Officer of Sensus Healthcare. "With these codes now in effect, physicians have greater reimbursement visibility and substantially improved economics to offer SRT and IG-SRT for the treatment of non-melanoma skin cancer, including an approximately 300% increase in the per-fraction delivery code. We believe this will meaningfully improve the quality of our sales pipeline, increase customer engagement, shorten the decision-making process for many prospective customers and, importantly, support continued diversification of our customer base."

Sensus Healthcare announced the filing of a lawsuit in the Circuit Court for the Fifteenth Judicial Circuit in and for Palm Beach County, Florida, against SkinCure Oncology alleging breach of contract related to unpaid amounts owed for Sensus products that have been delivered, accepted and deployed into clinical use. The complaint alleges that SkinCure has failed to remit millions of dollars for medical equipment that SkinCure has used since August 2025, but now refuses to pay in full. Sensus asserts that these amounts are contractually due and payable under the terms of the parties' Master Product Purchase Agreement. The lawsuit also includes an unspecified amount for related damages, as well as pre- and post-judgment interest and other fees and costs.